|
Platelet-Activating Factor Acetylhydrolase Deficiency
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension.
|
9759612 |
1998 |
|
Platelet-Activating Factor Acetylhydrolase Deficiency
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.
|
9472966 |
1998 |
|
Platelet-Activating Factor Acetylhydrolase Deficiency
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation.
|
9245731 |
1997 |
|
Platelet-Activating Factor Acetylhydrolase Deficiency
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke.
|
9412624 |
1997 |
|
Platelet-Activating Factor Acetylhydrolase Deficiency
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase.
|
8675689 |
1996 |
|
Platelet-Activating Factor Acetylhydrolase Deficiency
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
|
Platelet-Activating Factor Acetylhydrolase Deficiency
|
0.700 |
SusceptibilityMutation
|
disease |
CLINVAR |
|
|
|
|
Platelet-Activating Factor Acetylhydrolase Deficiency
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Platelet-Activating Factor Acetylhydrolase Deficiency
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Platelet-Activating Factor Acetylhydrolase Deficiency
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Logistic regression analysis showed close associations between MI with Lp-PLA2 and GG genotype at D166E, with odds ratios of 1.239 (1.023-2.017) and 9.863 (4.107-21.331), which suggested they were independent risk factors for the development of coronary heart disease.
|
31115024 |
2019 |
|
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Lp-PLA2 activity has important clinical value in CHD.
|
30770710 |
2019 |
|
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Plasma Lp-PLA2 level in patients with DKD was significantly higher and increased Lp-PLA2 level was independently associated with the incidence of DKD after adjustment for age, gender, duration of diabetes, glycated hemoglobin, body mass index, blood lipids, blood pressure, presence of coronary heart disease and carotid plaque, and use of statins (odds ratio = 1.545, P = 0.013).
|
30904742 |
2019 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The serum levels of ICAM-1, YKL-40, and Lp-PLA2 were correlated with different clinical types of CHD, but not well correlated the severity and extent of artery stenosis, suggesting that ICAM-1, YKL-40, and Lp-PLA2 might be involved in occurrence of instability of atherosclerotic plaque, and might reflect the severity of CHD mostly through reflecting the plaque stability.
|
29893361 |
2018 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, it is doubtful whether Lp-PLA2 will constitute a therapeutic target for the prevention of CHD.
|
29332572 |
2018 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Interaction between nonsynonymous polymorphisms in PLA2G7 gene and smoking on the risk of coronary heart disease in a Chinese population.
|
29728838 |
2018 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Lp-PLA2 mass was associated with CHD risk (HR: 1.02-1.24, 95% CI: 1.02-1.24, P=0.021).
|
28514697 |
2017 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Lipoprotein-associated phospholipase A2 (Lp-PLA<sub>2</sub>) is a marker of vascular inflammation associated with coronary heart disease and stroke.
|
28900364 |
2017 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Methods In 72,657 patients with coronary heart disease and 110,218 controls in 23 epidemiological studies, we genotyped five functional variants: four rare loss-of-function mutations (c.109+2T > C (rs142974898), rs144983904" genes_norm="7941">Arg82His (rs144983904), rs76863441" genes_norm="7941">Val279Phe (rs76863441), Gln287Ter (rs140020965)) and one common modest-impact variant (Val379Ala (rs1051931)) in PLA2G7, the gene encoding Lp-PLA<sub>2</sub>.
|
27940953 |
2017 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
|
28753643 |
2017 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Conclusion Plasma Lp-PLA2 concentration was independently associated with CHD in Chinese patients.
|
28222638 |
2017 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Greater Lp-PLA2 activity or mass was independently associated with cardiovascular events in patients with CHD, particularly in patients with stable CHD who were not receiving therapies for inhibiting Lp-PLA2.
|
27956130 |
2017 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Allelic tests showed that PLA2G7 rs9395208 and CD40 rs1800686 were significantly associated with CHD.
|
27461004 |
2016 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease.
|
26338298 |
2015 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in PLA2G7 were sequenced by DNA Sequencer and statistical analyses were performed to study the associations between polymorphisms and CHD.
|
25690150 |
2015 |